Why Humacyte Stock Is Trading 15% Higher Monday
Why Humacyte Stock Is Trading 15% Higher Monday
Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered Vessel (ATEV).
納斯達克股票代碼爲HUMA的Humacyte公司週一上漲，因其無細胞組織工程血管（ATEV）獲得美國食品和藥物管理局的再生醫學先進療法（RMAT）認定。
What To Know: This is the biotechnology company's third time receiving the RMAT designation which is designed to expedite the development and review of therapies for serious conditions.
需要了解的事項：這家生物技術公司已經第三次獲得RMAT認證，該認證旨在加快嚴重疾病療法的開發和審查。
The designation was specifically granted for the use of ATEV for patients with Advanced Peripheral Artery Disease (PAD).
認定是專門針對PAD晚期患者使用ATEV的。
Humacyte's ATEV is a implantable conduit designed for blood vessel replacement and repair. It showed low infection rates in clinical trials and it is available off-the-shelf for immediate use by surgeons. The novel treatment is beneficial for PAD patients who may not have suitable veins for standard lower leg bypass procedures.
Humacyte的ATEV是一種可植入的導管，設計用於血管置換和修復。它在臨床試驗中顯示出低感染率，並可隨時供外科醫生使用。這種新型治療對於可能沒有適合標準下肢搭橋手術的PAD患者非常有益。
"We are excited that this additional designation has been granted in advanced PAD, as we expect that it will further strengthen our communication with the FDA and expedite the development of our ATEV in this important indication," said Dr. Cindy Cao, chief regulatory officer at Humacyte.
Humacyte首席監管官Cindy Cao博士表示：“我們很高興在PAD晚期獲得了這一額外的認定，因爲我們預計這將進一步加強我們與FDA的溝通，並加速我們ATEV在這一重要適 indication的開發。”
Related Link: Why Complete Solaria Stock Is Rising
相關鏈接：爲什麼Complete Solaria的股票正在上漲
HUMA Price Action: Humacyte stock is trading 15% higher at $5.52 at the time of writing per data from Benzinga Pro.
HUMA價格行動：根據Benzinga Pro的數據，Humacyte股票在撰寫時以5.52美元的價格上漲了15％。
Image: Photo Via Shutterstock
圖像：通過shutterstock的照片
譯文內容由第三人軟體翻譯。